PMC:7534795 / 1335-2027
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T15726 | 91-96 | Body_part | denotes | lipid | http://purl.org/sig/ont/fma/fma67264 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T13 | 395-403 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T14 | 519-527 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T53704 | 63-64 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T74203 | 532-537 | http://purl.obolibrary.org/obo/CLO_0009985 | denotes | focus |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T12 | 2-6 | Chemical | denotes | acid | http://purl.obolibrary.org/obo/CHEBI_37527 |
| T13 | 8-11 | Chemical | denotes | EPA | http://purl.obolibrary.org/obo/CHEBI_28364|http://purl.obolibrary.org/obo/CHEBI_36006 |
| T15 | 17-37 | Chemical | denotes | docosahexaenoic acid | http://purl.obolibrary.org/obo/CHEBI_36005 |
| T16 | 33-37 | Chemical | denotes | acid | http://purl.obolibrary.org/obo/CHEBI_37527 |
| T17 | 39-42 | Chemical | denotes | DHA | http://purl.obolibrary.org/obo/CHEBI_16016|http://purl.obolibrary.org/obo/CHEBI_28125|http://purl.obolibrary.org/obo/CHEBI_28689|http://purl.obolibrary.org/obo/CHEBI_36005 |
| T21 | 65-70 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
| T22 | 91-96 | Chemical | denotes | lipid | http://purl.obolibrary.org/obo/CHEBI_18059 |
| T23 | 264-269 | Chemical | denotes | PUFAs | http://purl.obolibrary.org/obo/CHEBI_26208 |
| T24 | 280-291 | Chemical | denotes | metabolites | http://purl.obolibrary.org/obo/CHEBI_25212 |
| T25 | 326-331 | Chemical | denotes | PUFAs | http://purl.obolibrary.org/obo/CHEBI_26208 |
| T26 | 345-353 | Chemical | denotes | adjuvant | http://purl.obolibrary.org/obo/CHEBI_60809 |
| T27 | 606-611 | Chemical | denotes | PUFAs | http://purl.obolibrary.org/obo/CHEBI_26208 |
| T28 | 622-633 | Chemical | denotes | metabolites | http://purl.obolibrary.org/obo/CHEBI_25212 |
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T57624 | 461-473 | http://purl.obolibrary.org/obo/GO_0009405 | denotes | pathogenesis |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T10 | 215-413 | Sentence | denotes | Considering the favorable safety profile for n-3 PUFAs and their metabolites, it is reasonable to consider n-3 PUFAs as potential adjuvant therapies for the clinical management of COVID-19 patients. |
| T11 | 414-634 | Sentence | denotes | In this article, we provide an overview of the pathogenesis of cardiovascular complications secondary to COVID-19 and focus on the mechanisms that may contribute to the likely benefits of n-3 PUFAs and their metabolites. |
| T12 | 636-651 | Sentence | denotes | 1 Introduction |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 41 | 404-412 | Species | denotes | patients | Tax:9606 |
| 45 | 8-11 | Chemical | denotes | EPA | MESH:D015118 |
| 46 | 17-37 | Chemical | denotes | docosahexaenoic acid | MESH:D004281 |
| 47 | 39-42 | Chemical | denotes | DHA | MESH:D004281 |
| 48 | 91-96 | Chemical | denotes | lipid | MESH:D008055 |
| 49 | 260-269 | Chemical | denotes | n-3 PUFAs | MESH:D015525 |
| 50 | 322-331 | Chemical | denotes | n-3 PUFAs | MESH:D015525 |
| 51 | 602-603 | Chemical | denotes | n | MESH:D009584 |
| 61 | 395-403 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 62 | 477-505 | Disease | denotes | cardiovascular complications | MESH:D002318 |
| 63 | 519-527 | Disease | denotes | COVID-19 | MESH:C000657245 |